We then verify that the NF-κB pathway is the underlying pathway regulated by rosuvastatin and HMGB1.In vivo experiments also reveal that rosuvastatin inhibits IDD progression by alleviating pyroptosis and senescence and downregulating HMGB1 and p65. Here, HMGB1 is linked to intervertebral disk degenerative disorder.